Katie Tamony is the chief marketing officer and trend spotter for Monrovia Nursery, the nation’s largest grower of premium ...

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

This current WNBA offseason is set up to be fascinating for several reasons. The most notable is the ongoing Collective ...

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for ...

SAN DIEGO – 17 October 2025 – General Atomics Aeronautical Systems, Inc. (GA-ASI) has been contracted by the U.S. Navy to ...

The Philippine National Police Anti-Cybercrime Group (PNP-ACG) has strengthened its drive against digital financial crimes ...

Gold has long been the inflation hedge of choice, but bitcoin has emerged as a credible digital complement. Read more here.

The Wilkes-Barre Fire Department has a full complement of full-time paramedics again with the hire Thursday of an experienced ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

Results of a meta-analysis showed that a history of allergies, multiorgan involvement, and decreased complement levels were linked to higher risk for IgG4-RD relapse.

A new British study reported that treatment with intravitreal complement inhibitors (IVCIs) for geographic atrophy (GA) was viewed favorably by patients if the treatment was thought to impart visual ...